治疗病态晚期前列腺癌的辅助放射治疗:一种随机临床试验
Ian M Thompson1, Catherine M Tangen, Jorge Paradelo
1Department of Urology, University of Texas Health Science Center at San Antonio, MC-7845, 7703 Floyd Curl Dr, San Antonio, TX 78229-3900, USA. thompsoni@uthscsa.edu
JAMA
|November 16, 2006
概括
前列腺癌手术后的辅助放射治疗显著减少了PSA复发和疾病复发. 然而,它并没有显著改善无转移或整体存活率,并增加了不良反应.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 尿道瘤学 尿道瘤学
背景情况:
- 经过激进前列腺切除术后的晚期前列腺癌仍然是一个临床挑战.
- 对这些患者的最佳管理策略尚未明确.
- 尽管早期的检测工作,但有很大比例的患者患有病理性晚期疾病.
研究的目的:
- 评估辅助放射治疗在改善无转移存活率方面的疗效.
- 评估辅助放射治疗对前列腺特异抗原 (PSA) 复发和无复发存活率的影响.
- 确定辅助放射治疗对pT3 N0 M0前列腺癌患者的整体存活率和术后并发症的影响.
主要方法:
- 一个随机的,前性的,多机构的临床试验,涉及425名患有病态晚期前列腺癌的前列腺切除术后的男性.
- 患者被分配接受辅助外部光束放射治疗或常规护理与观察.
- 无转移生存率是主要结局,次要结局包括PSA复发,无复发生存率和整体生存率.
主要成果:
- 辅助放射治疗显著减少了前列腺特异抗原 (PSA) 复发 (HR,0.43;P<.001) 和疾病复发 (HR,0.62;P=.001).
- 虽然趋势有利于辅助放射治疗的无转移生存率 (HR,0.75;P = .06) 和总生存率 (HR,0.80;P = .16),但这些趋势没有达到统计学意义.
- 副作用,包括直肠并发症和尿道狭窄,在放射治疗组中更为频繁.
结论:
- 在急性前列腺切除术后用于晚期前列腺癌的辅助放射治疗显著降低了PSA复发和疾病复发的风险.
- 无转移存活率和整体存活率的改善没有统计学意义.
- 副作用的发生率增加需要仔细考虑辅助放射治疗的风险和益处.
相关概念视频
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...


